DMRA EBITDA | DAMORA THERAPEUTICS, INC.

DAMORA THERAPEUTICS, INC. (DMRA) EBITDA

2026-06-30: Basis Reported; EBITDA (m); Operating income -$34.99M; Depreciation and amortization (m).
2026-03-31: Basis Reported; EBITDA (m); Operating income -$30.81M; Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA (m); Operating income -$3.16M; Depreciation and amortization (m).
2025-06-30: Basis Reported; EBITDA (m); Operating income -$3.42M; Depreciation and amortization (m).

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	(m)	-$34.99M	(m)	(m)	(m)	(m)	-$21.87M*	(m)	$25.54M	(m)	$255.00K
2026-03-31	Reported	(m)	-$30.81M	(m)	(m)	(m)	(m)	-$20.60M	(m)	$23.78M	(m)	$42.00K
2025-09-30	Reported	(m)	-$3.16M	(m)	(m)	(m)	(m)	-$2.62M*	(m)	$1.42M	(m)	$0.00
2025-06-30	Reported	(m)	-$3.42M	(m)	(m)	(m)	(m)	-$2.24M*	(m)	$1.47M	(m)	$4.00K
2025-03-31	Reported	(m)	-$2.60M	(m)	(m)	(m)	(m)	-$2.44M	(m)	$678.00K	(m)	$2.00K
2024-09-30	Reported	(m)	-$3.84M	(m)	(m)	(m)	(m)	-$3.65M*	(m)	$1.09M	(m)	$7.00K
2024-06-30	Reported	(m)	-$5.58M	(m)	(m)	(m)	(m)	-$4.10M*	(m)	$1.83M	(m)	$42.00K
2024-03-31	Reported	(m)	-$5.74M	(m)	(m)	(m)	(m)	-$5.94M	(m)	$2.46M	(m)	(m)
2023-09-30	Reported	(m)	-$8.58M	(m)	(m)	(m)	(m)	-$8.45M*	(m)	$2.55M	(m)	(m)
2023-06-30	Reported	(m)	-$11.16M	(m)	(m)	(m)	(m)	-$7.85M*	(m)	$8.09M	(m)	(m)
2023-03-31	Reported	(m)	-$13.49M	(m)	(m)	(m)	(m)	-$9.13M	(m)	$10.36M	(m)	(m)
2022-09-30	Reported	(m)	-$13.62M	(m)	(m)	(m)	$138.00K*	-$9.85M*	(m)	$10.49M	(m)	(m)
2022-06-30	Reported	(m)	-$17.12M	(m)	(m)	(m)	-$26.00K*	-$14.84M*	(m)	$13.71M	(m)	(m)
2022-03-31	Reported	(m)	-$16.94M	(m)	(m)	(m)	$43.00K	-$6.80M	(m)	$13.23M	(m)	(m)
2021-09-30	Reported	(m)	-$12.94M	(m)	(m)	(m)	$47.00K*	-$9.16M*	(m)	$9.75M	(m)	(m)
2021-06-30	Reported	(m)	-$12.27M	(m)	(m)	(m)	$115.00K*	-$11.17M*	(m)	$8.63M	(m)	(m)
2021-03-31	Reported	(m)	-$13.55M	(m)	(m)	(m)	$65.00K	-$14.15M	(m)	$9.99M	(m)	(m)
2020-09-30	Reported	(m)	-$10.17M	(m)	(m)	(m)	(m)	-$8.58M*	(m)	$7.65M	(m)	(m)
2020-06-30	Reported	(m)	-$6.34M	(m)	(m)	(m)	(m)	-$7.13M*	(m)	$4.51M	(m)	(m)
2020-03-31	Reported	(m)	-$5.83M	(m)	(m)	(m)	(m)	-$7.98M	(m)	$4.71M	(m)	(m)
2019-09-30	Reported	(m)	$4.83M	(m)	(m)	(m)	(m)	(m)	(m)	$3.67M	(m)	(m)

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	(m)	-$210.87M	(m)	(m)	(m)	(m)	-$6.73M	(m)	$26.88M	(m)	$50.00K
2024-12-31	Reported	(m)	-$22.26M	(m)	(m)	(m)	(m)	-$18.62M	(m)	$6.40M	(m)	$41.00K
2023-12-31	Reported	(m)	-$39.91M	(m)	(m)	(m)	(m)	-$36.91M	(m)	$23.77M	(m)	$0.00
2022-12-31	Reported	(m)	-$61.21M	(m)	(m)	(m)	$196.00K	-$42.93M	(m)	$48.21M	(m)	$0.00
2021-12-31	Reported	(m)	-$52.23M	(m)	(m)	(m)	$223.00K	-$52.31M	(m)	$38.49M	(m)	$0.00
2020-12-31	Reported	(m)	-$33.64M	(m)	(m)	(m)	(m)	-$38.20M	(m)	$24.63M	(m)	$0.00
2019-12-31	Reported	(m)	$38.97M	(m)	(m)	(m)	(m)	-$19.33M	(m)	$19.74M	(m)	$0.00

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
HARROW, INC. (HROW)	United States	$1.240B	-42.77
Avalyn Pharma Inc. (AVLN)	United States	$1.267B
OPKO HEALTH, INC. (OPK)	United States	$1.220B	-15.59
LB PHARMACEUTICALS INC (LBRX)	United States	$1.220B	-10.87
First Tracks Biotherapeutics, Inc. (TRAX)	United States	$1.280B
Bicara Therapeutics Inc. (BCAX)	United States	$1.309B	-10.55
Jaguar Health, Inc. (JAGX)	United States	$1.184B
Latigo Biotherapeutics, Inc. (LTGO)	United States	$1.176B
Tyra Biosciences, Inc. (TYRA)	United States	$1.337B	-12.83
Kardigan, Inc. (KARD)	United States	$1.346B